Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

If you’re exploring weight loss or diabetes treatments, you may have come across Zepbound and Mounjaro. Though they have different names, they’re essentially the same medication created and produced ...

Retatrutide targets GIP and GLP-1 – the same as Lilly’s fast-growing diabetes therapy Mounjaro (tirzepatide ... with the highest dose on test (12 mg once weekly), with participants ...

“If you’re not having fun, what’s the point?” During X Games Aspen, 15-year-old snowboarder Lily Dhawornvej was the third rider in as many days to express this sentiment. Chloe Kim said ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion and $5.15 per share ... growth for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight ...

The results come after the maker of weight-loss drugs Zepbound and Mounjaro in January lowered expectations for its fourth-quarter sales. Eli Lilly (LLY) is set to report fourth-quarter earnings ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.